Kodiak (NASDAQ: KOD) CFO sells 30,000 shares in planned option unwind

What happened

Kodiak Sciences Inc. (NASDAQ: KOD) Chief Financial Officer John A. Borgeson sold 30,000 shares on 2026-10-21. The filing says the sales were spread across multiple transactions at weighted-average prices from $87.67 to $94.91 a share. That brought in about $2.70 million. Borgeson held 211,930 shares after the sale. The form says the trades were made under a Rule 10b5-1 trading plan adopted on September 29, 2025.

It also says the shares sold came from stock options exercised the same day at a $2.49 exercise price. The option covered 30,000 shares and was set to expire on 08/04/2034.

Key numbers

Metric	Latest	Change	Source
Shares sold	30,000 shares		SEC Form 4
Sale price range	from $87.67 to $94.91 per share		SEC Form 4
Total sale value	about $2.70 million		SEC Form 4
Shares held after sale	211,930 shares		SEC Form 4
Sale size as share of pre-trade holding	12.4%		Calculated from SEC Form 4

Read more: Kodiak Sciences (KOD) stock analysis and investment case

Why it matters

OptimistFi's case is that Kodiak's value depends on whether its ABC platform can produce clearly differentiated, financeable ophthalmology medicines before cash burn or competition absorbs the upside. This filing does not change that core operating question, but it gives investors a clean insider-ownership update and shows how a planned sale can follow exercised options. The 30,000-share sale was about 12.4% of Borgeson's pre-trade 241,930-share holding.

The sale prices sat far above the $2.49 exercise price, so the filing reads as an exercise-and-sale sequence. Borgeson still held 211,930 shares after the sale, so the filing shows continued ownership rather than a full exit. The strongest caveat is that the filing ties the sale to a Rule 10b5-1 plan and same-day option exercises, which makes it look mechanical rather than a fresh judgment on the company.

For investors, that means the headline is about insider liquidity, not a new operational disclosure. That keeps the filing firmly in the category of insider activity rather than a business update.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Kodiak Sciences Inc.'s next quarterly report is the next scheduled test of the case. A report that advances the ABC platform or eases cash-burn pressure would help, while a routine quarter would leave this filing as mostly a trading record. If the report brings no fresh clinical or balance-sheet detail, this filing will stay a limited signal. Until then, the form mainly marks the size of Borgeson's remaining stake and the preplanned terms of the sale.

The report will matter more if it updates cash burn or clinical progress on the ABC platform.

More from OptimistFi

• KOD stock: the Kodiak Sciences thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps